Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tosedostat + Capecitabine in Metastatic Pancreatic Adenocarcinoma
NCT02352831Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2015
- Primary completion
- Oct 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of tosedostat in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Recommended Phase II Dose of Tosedostat, Number of Participants Who Experience Dose-limiting Toxicities and 1 more. Started Aug 2015; status: terminated.
02
Drugs
tosedostat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02352831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352831.